COVID-19 $3m fund to support R&D Tax claimants

In response to the Covid-19 business impact on cash poor technology companies claiming the R&D Tax Incentive, TCF Services in partnership with R&D Capital Partners is offering reduced rates for a 6 month period only to provide:

       R&D Tax prepayment loans of up to 80% against expected 18/19 or 19/20 financial year R&D tax cash refunds and;

       R&D Tax claim services including the establishment of compliant record keeping practices.

       Free scoping of other grant opportunities

R&D Tax Incentive Prepayment Funding Service

R&D Capital Partners is a specialist financier that provides Australian based firms undertaking research and development activities the ability to use their projected R&D Tax Incentive benefit as security to access funding, up to a year before the benefit can be claimed through the tax system.

R&D companies with less than $20 million in annual turnover who are eligible to receive a 43.5% refundable tax offset, may drawdown a prepayment loan of up to 80% of the calculated benefit after incurring eligible R&D expenditure in the current year.

Our typical borrower is an early stage business focused on R&D which requires new funding between $50,000 to $3 million to support its R&D program through to its next milestone.

Our focus on the tax return as collateral allows us to provide funding solutions not provided by the traditional banking community. R&DCP lends to businesses across all industry sectors which to date have included healthcare, education, technology, business services, manufacturing and agriculture.

The critical focus is the eligibility of the R&D program.

Visit TCF Services website to learn more

What our clients say

  • Minomic is an immuno-oncology company developing “next-gen” cancer testing and immuno-therapeutics for global markets.  R&D Capital Partners’ understanding of our research activities avoided any delays in implementing their innovative loan package.  With their financial support in place we were able to undertake our various pilot trials in the US and are able to progress our planned human therapeutic trials utilising our proprietary technology.  The data from these trials has strengthened our intellectual property which, in turn, underpins our ability to raise new equity.  This new equity together with further loans from R&DCP will be used to commercialise our diagnostic test and fund further therapeutic development.

    Minomic
    David Burdis – Chief Operations and Financial Officer
  • Truscreen specialises in the R&D and commercialisation of technologies for real time identification of cancerous tissue.  R&D Capital Partners’  innovative funding solution allowed us to extend our R&D program without having to raise additional equity to fund our China Food and Drug Administration approval in April 2015.  With this significant milestone achieved, we were then able to raise $5 million in fresh equity in June 2015 at $0.25c per share representing a 50% increase over the price of $0.16 per share prior to the involvement of R&D Capital Partners.

    Truscreen
    Martin Dillon – Chief Executive Officer
  • From butchers paper to the cloud, zipMoney proprietarily developed a digital credit and payments engine to facilitate point of sale financial transactions. In our formative years, R&D Capital Partners was pivotal in supporting our accelerated growth. Their deep understanding of our model and R&D activities, allowed R&DCP to turn around an expedited funding solution that met out capital needs and bridged us to the end of year full refund. By utilising R&DCP together with our seed investors, zipMoney was able to prove out its business model, before raising equity and debt from traditional markets leading to a successful listing on the Australian Stock Exchange in September 2015.

    Zip Money
    Larry Diamond – Director